Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $13.95 Total: $1,395.00 50 $16.12 Total: $806.00 25 $18.91 Total: $472.75 10 $22.32 Total: $223.20 5 $26.35 Total: $131.75

Novel antifungal and fungicidal agent

Novel K channel opener; Glyburide-Reversible Cardioprotective Agent with Minimal Vasodilator Activity

5HT1B/1D agonist

Novel potent, selective inhibitor of AAK1 (adaptor associated kinase 1), having the appropriate combination of solubility and charge required for microiontophoresis

Novel PD-1/PD-L1 Inhibitor

Novel PD-L1 Inhibitor

Novel Highly Selective LRRK2 Inhibitor

Novel activator of BMP signaling, enhancing osteoblast differentiation, targeting HECT domain of ubiquitin ligase Smurf1, up-regulating the protein level of Smad1/5

Novel activator of BMP signaling, enhancing osteoblast differentiation, targeting HECT domain of ubiquitin ligase Smurf1, up-regulating the protein level of Smad1/5

Metabolite of BML277 which is a selective checkpoint kinase 2 inhibitor

Potent and selective inhibitor of Cdk5/p25, protecting large population of cells against non-A

Novel potent cyclin-dependent kinases (CDK) inhibitor, inducing a strong cell cycle alteration

Novel inhibitor of RNA polymerase I, causing nucleolar stress and showing potent anticancer activity across many tumor types

Novel LRP5/6-sclerostin interaction inhibitor, recovering the downregulated activity of the Wnt/β-catenin signaling pathway by competitive binding to the LRP5/6-sclerostin complex

Novel potent EGFR inhibitor

Dual thromboxane synthase inhibitor and thromboxane receptor antagonist

Original TXA2 modulator, inhibiting the action of thromboxane A2 and 8-iso-prostaglandin F2alpha

Inhibitor of Marburg virus (MARV) growth at noncytotoxic concentrations

Inhibitor of calpain, cathepsin L and cathepsin B

Novel ERK inhibitor, inducing breast cancer cell apoptosis via mitochondrial pathway but independent on Ras/Raf/MEK pathway

Potent 14-3-3 inhibitor

Natural Potent 14-3-3 inhibitor

Natural anti-coronavirus agent

Bradykinin antagonist, causing impressive growth inhibition of lung and prostate tumors, displaying superior in vivo inhibitory effects than convential chemotherapeutic drugs

Novel inhibitor of the expression of anti-apoptotic protein survivin and membrane-bound efflux pump ATP binding cassette B 1 (ABCB1, p-glycoprotein), presumably via signal transducer and activator of transcription 3 (Stat3), inhibiting human prostate canc

Novel effective inhibitor of survivin expression at both the mRNA and protein levels in vitro, significantly reducing survivin in bone metastatic C4-2 tumors

Novel inhibitor of survivin transcription through a signal transducer and activator of transcription 3 (Stat3)-dependent mechanism, inhibiting tissue expression of survivin and inducing apoptosis in C4-2 skeletal tumor

Novel potent and selective bumped kinase inhibitor (BKI) CpCDPK1 IC 50 0.005 µM

Novel potent and selective bumped kinase inhibitor (BKI) CpCDPK1 IC 50 0.0025 µM